Ridgeback Biotherapeutics LP Announces the U.S. Food and Drug Administration Approvel of EbangaTM for Ebola

Ebanga | December 29, 2020

Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients.

Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure.

Wendy Holman, CEO and co-founder of Ridgeback, said: “I speak on behalf of the entire Ridgeback Bio team when I say thank you to all of the dedicated and thoughtful groups who helped contribute to this historic and important product approval. Ridgeback is grateful to NIAID’s Vaccine Research Center (VRC) and the Democratic Republic of the Congo’s (DRC) Institut National pour la Recherche Biomédicale (INRB). Specifically, the brilliance of three individuals needs to be acknowledged -- Dr. Nancy Sullivan (VRC), Dr. John Mascola (VRC) and Professor Jean-Jacques Muyembe-Tamfum (INRB). It was their mission to create a lyophilized single-use Ebola treatment, and in partnership with the team at Ridgeback, that vision became a reality. We would also like to thank FDA leadership and the Ebanga review team at FDA’s Division of Antivirals (DAV) for their focused and thorough review of this product. Finally, the true heroes are the patients and their families who allowed themselves to be carried away from their homes – not knowing if they would ever return – in order to enroll in a randomized controlled trial at the Ebola treatment centers during the 2018-2020 Ebola outbreak in the DRC. Your trust and belief in science, innovation and the people caring for you has transformed Ebola forever. Thanks to you, Ebola is now a treatable disease.”


Obtaining human embryonic stem cells through the process of therapeutic cloning has important applications in science and medicine.Shoukhrat Mitalipov's team at Oregon Science and Medicine University has been the first to obtain viable human embryonic stem cells using this technique. In the future, patients' organs could be repaired with stem cells obtained from adult cells from their skin, an option that would not cause rejection. Mitalipov's findings are an important step forward towards those future treatments.


Obtaining human embryonic stem cells through the process of therapeutic cloning has important applications in science and medicine.Shoukhrat Mitalipov's team at Oregon Science and Medicine University has been the first to obtain viable human embryonic stem cells using this technique. In the future, patients' organs could be repaired with stem cells obtained from adult cells from their skin, an option that would not cause rejection. Mitalipov's findings are an important step forward towards those future treatments.

Related News


PostEra announces $260M multi-target strategic AI Lab collaboration with Pfizer

PostEra | January 12, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's data, and PostEra's pioneering innovations in generative chemistry and synthesis-aware design. PostEra will receive an upfront payment of $13M and is eligible to receive additional milestone payments totalling up to $248M should all milestones be achieved, in addition to tiered royalties on any approved products arising out of the collaboration. The AI Lab will tightly integrate drug discovery with technology development to ensure a continuous feedback loop that refines both the process and predictions from the platform. The vision of the AI Lab is to combine Pfizer's expertise and data with PostEra's technology to advance these drug discovery programs, while also producing an integrated state-of-the-art platform to be deployed across Pfizer's in-house, preclinical drug discovery efforts. "We think the best way to build leading technology is to have its development tightly integrated with live drug discovery programs", said Dr. Alpha Lee, Chief Scientific Officer of PostEra. "We're pleased that we are expanding the existing collaboration to do exactly this and to reap the AI advantage in improving preclinical drug discovery," Aaron Morris, CEO of PostEra "At Pfizer, we believe digital technologies, including artificial intelligence and machine learning, hold great potential to aid the discovery of novel approaches to prevent, cure, and treat disease for patients in need," said Charlotte Allerton, Head of Medicine Design, Pfizer. "We're excited to extend our collaboration with PostEra to further build on our current capabilities." The company today also announced its $24M Series A financing. The new funding will enable PostEra to further expand its partnered drug discovery programs, initiate internal drug discovery programs, as well as further develop its AI-first medicinal chemistry platform. About PostEra PostEra was founded in 2019 and its technology is built on pioneering academic research done by its founding scientists. PostEra's technology addresses some of the key challenges in drug discovery R&D by integrating molecular design with chemical synthesis. PostEra advances small molecule programs through partnerships with biopharma, working on its own internal pipeline, and also offering some of its synthesis technology via its Manifold web platform. PostEra also launched and now helps lead the world's largest open-science drug discovery effort; COVID Moonshot.

Read More


BioInvent and Transgene Receive CTA Approval for Phase l/lla Study of Novel Oncolytic Vaccinia Virus BT-001

BioInvent | December 22, 2020

BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vaccinia virus BT-001. BT-001 is a best-in-class oncolytic Vaccinia virus. It has been produced utilizing Transgene's Invir.IO™ stage and its protected large-capacity VVcopTK-RR-oncolytic virus, which has been designed to encode both a Treg- depleting human recombinant anti-CTLA4 antibody response created by BioInvent's proprietary n-CoDeR®/F.I.R.S.T™ stages, and the human GM-CSF cytokine. By specifically focusing on the tumor microenvironment, BT-001 is relied upon to inspire a lot more grounded and more successful antitumoral reaction. Conveying the anti-CTLA4 antibody response straightforwardly to the tumor microenvironment will permit a neighborhood remedial movement and will in this manner enormously increment the security and tolerability profile of the monoclonal immunizer by antibody foundational introduction. BT-001 is being co-created through a 50/50 collaboration among BioInvent and Transgene.

Read More


Precision Coating Announces Merger with N2 Biomedical to Expand Medical Coatings Platform

N2 Biomedical | September 20, 2021

Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company. N2 Biomedical, an Ampersand Capital Partners portfolio company, provides nano-engineered surface treatment and coating services to the medical device industry with its low-temperature Ion Implantation Surface Treatments and Ion Beam Assisted Deposition (IBAD) technologies. We are very excited to add N2's technologies and people to Precision Coating. N2 extends our coating platform technologies in ways that enhance our value proposition for customers. This is particularly true in orthopedics, where we can now offer engineered coating solutions across both instruments and implants. The two companies have a great deal of complementarity between market focus, customer overlap, product functional properties, and operational execution, not to mention geographic proximity. - Bill Ellerkamp, President of Precision Coating About Precision Coating For over 50 years, Precision Coating has collaborated with medtech partners to realize their product design and manufacturing goals by providing highly engineered coating and specialized finishing services. Among the portfolio of medical coatings and application solutions, GlideLine™ and InfiNiTiCoat™ coatings comprise the broadest offering of applied fluoropolymer (PTFE) coatings for interventional and advanced surgical devices, and the patented MICRALOX® portfolio is the recognized standard for superior aluminum anodizing finishes for barrier properties, corrosion resistance, and extended product life cycles, targeting orthopedic and advanced surgical instruments. Precision Coating partners with early-stage device innovators through major medical equipment manufacturers, deploying comprehensive solutions—from concept to commercialization—and offering flexible prototype work through high-volume coating application, finishing, and printing services. The company operates facilities in Massachusetts, Rhode Island, and Costa Rica, and serves customers worldwide, offering seamless supply chain support. About N2 Biomedical Established in 2013, N2 provides coating and surface treatment development and application services for implantable and other medical devices utilized in orthopedic, cardiovascular, and other healthcare end-markets. N2 is ISO 13485 certified, FDA GMP compliant, and operates in a 27,000-square-foot facility with laboratory, manufacturing, and cleanroom space to service all customer and regulatory requirements. The company leverages its proprietary processes and equipment to provide customized solutions that enhance the characteristics of various materials in critical applications, including lubricity, infection resistance, biocompatibility and tissue integration, and wear and corrosion resistance. About Ampersand Capital Partners Founded in 1988, Ampersand is a middle-market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors.

Read More